Carotenoids modulate the hallmarks of cancer cells. (October 2015)

• Record Type: Journal Article
• Authors: Niranjana, R; Gayathri, R; Nimish Mol, Stephen; Sugawara, T; Hirata, T; Miyashita, K; Ganesan, P
• Is Part Of: Journal of functional foods. Volume 18:Part B(2016)
• Page Start: 968
• Page End: 985
• Publication Date: 2015-10
• Subjects: HL-60 human promyelocytic leukemia cell line -- U-937 human leukemic monocyte lymphoma cell line -- AtT20 mouse pituitary epithelial-like tumor cell line -- DU145 and PC-3 human prostate cancer cell lines -- LNCaP androgen-sensitive human prostate adenocarcinoma cell line -- Hep3B and HepG2 human hepatocellular carcinoma cell lines -- HT-29 HCT-116, CaCo2, COLO 320 HSR, DLD-1, T-84 and WiDr, human colorectal adenocarcinoma cell lines -- MCF-7 MDA-MB-468 and SK-BR-3, human breast adenocarcinoma cell lines -- KB-1 human mouth epidermal carcinoma cell line -- A549 human alveolar adenocarcinoma epithelial cell line -- K562 human erythromyeloblastoid leukemia cell line -- BxPC-3 and MIA-PaCa-2 human pancreatic adenocarcinoma cell lines -- MGC-803 and AGS human gastric adenocarcinoma cell lines -- AH109A rat ascites hepatoma cell line -- SK-Hep-1 human hepatic adenocarcinoma cell line -- YTMLC-90 human lung cancer cell line -- SK-MEL-2 human melanoma cell line -- SP6.6 and C918 human uveal melanoma cell lines -- C3H10T1/2 mouse embryonic mesenchymal cell line -- 143B human osteosarcoma cell line -- GOTO and SK-N-BE(2) human neuroblastoma cell lines -- B16F-10 mouse melanoma cell line -- TE-4 human esophageal carcinoma cell lines -- EJ-1 human urinary bladder cancer cell line -- HUVEC human umbilical vein endothelial cells -- ROS reactive oxygen species -- ROO peroxyl radical -- ABTS 2, 2′-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) radical -- ICR imprinted control region -- Skp2 S-phase kinase associated protein 2 -- pRB retinoblastoma protein -- CK8/18 cytokeratin 8/18 -- CK19 cytokeratin 19 -- Cdc cell division control protein -- p21WAF1/Cip1 cyclin-dependent kinase inhibitor 1 -- CDK cyclin-dependent kinase -- p15INK4b cyclin-dependent kinase 4 inhibitor B -- p27KIP cyclin-dependent kinase inhibitor 1B -- PCNA proliferating cell nuclear antigen -- Nrf2 nuclear factor erythroid 2-related factor 2 -- GADD45α and GADD153 growth arrest and DNA-damage-inducible proteins -- Cx43 and Cx32 connexins -- SAPT/JNK stress-activated protein kinase/c-Jun N-terminal kinase -- ERK extracellular signal-regulated kinase -- PARP poly-ADP-ribose polymerase -- Bcl-2 B-cell lymphoma 2 -- Bax Bcl-2 associated X protein -- Bcl-xL B-cell lymphoma-extra large -- BAD Bcl-2-associated death promoter -- PPAR-γ peroxisome proliferator-activated receptor gamma -- Akt Akt-murine thymoma viral oncogene/protein kinase B -- Rac 1 Ras-related C3 botulinum toxin substrate 1 -- Rho Ras-like small GTPase protein -- Nm23-H1 non-metastatic protein 23 homologue 1 -- ATM ataxia-telangiectasia-mutated -- NF-κB nuclear factor kappa-B -- uPA urokinase plasminogen activator -- PAI-1 plasminogen activator inhibitor-1 -- COX cyclooxygenase -- DR5 death receptor 5 -- FGF fibroblast growth factor -- FGFR fibroblast growth factor receptor -- AIF apoptosis inducing factor -- XIAP X-linked inhibitor of apoptosis protein -- JAK/STAT Janus kinase/signal transducer and activator of transcription -- EGFR epidermal growth factor receptor -- TRAIL TNF-related apoptosis inducing ligand -- MMP matrix metalloproteinase -- VEGF vascular endothelial growth factor -- VEGFR vascular endothelial growth factor receptor -- GLUT-1 glucose transporter-1 -- HIF-1α hypoxia-inducible factor- 1α -- TIMP-1 tissue inhibitor of MMP-1 -- PI3K phosphoinositide 3 kinase -- CXR4 C-X-C chemokine receptor type 4 -- CD44 cluster of differentiation 44 -- DBA dilute brown non-agouti -- IL-12 interleukin-12 -- INF-γ interferon gamma -- VE-cadherin vascular endothelial-specific cadherin -- WHO World Health Organization -- PSA prostate specific antigen -- XRCC1 X-ray repair cross-complementing protein 1 -- ER estrogen receptor -- PR progesterone receptor -- DHA docosahexaenoic acid -- ODC ornithine decarboxylase -- CIN cervical intra-epithelial neoplasia -- HPV human papilloma virus; Carotenoids -- Cell cycle arrest -- Apoptosis -- Anti-metastasis -- Anti-angiogenesis -- Epidemiology; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2014.10.017
• Languages: English
• ISSNs: 1756-4646

Abstract

Highlights: Carotenoids modulate the hallmarks of cancer cells through multiple molecular mechanisms An increase in the circulating level of carotenoids reduced the risk of cancers Marine carotenoids possess comparatively potent anti-cancer effects over terrestrial carotenoids Abstract: Biologically active compounds are considered as powerful food factors that elicit profound effects on the maintenance of human health, and disease prevention. The research into how bioactive compounds work and their role in disease prevention in vitro and in vivo is rapidly expanding. Carotenoids are one among several classes of biologically active compounds that have been reported to possess greater antioxidant and anti-cancer activity. Today, this emerging class of nutrients is the driving force in the nutritional supplement industry, and serves as a new frontier in cancer and cardiovascular research. Cancer is one of the leading causes of death worldwide. It is the second most common disease responsible for maximum mortality with about 8.2 million deaths, and the global cancer burden rises to 14.1 million new cases in 2012. This review mainly focused to summarize the anti-cancer therapeutic targets of carotenoids by highlighting the important hallmarks of cancer in terms of (i) cell cycle arrest, (ii) resistance to apoptosis, (iii) metastasis and (iv) angiogenesis alongside the relation of carotenoids in cancer epidemiology.